Why Impax Laboratories' Shares Soared

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of specialty pharmaceutical company Impax Laboratories (Nasdaq: IPXL  ) were climbing higher today, gaining as much as 11% in intraday trading after the company reported second-quarter results.

So what: It was a big quarter for Zomig, the migraine treatment that Impax licenses from AstraZeneca (NYSE: AZN  ) . Zomig helped push the company's Impax Pharmaceuticals division to a profit and aided in the company's big jump in non-GAAP earnings -- from $0.19 per share last year to $0.60 this year. The bulk of the company's earnings did, however, still come from its Global Pharmaceuticals division. That segment benefitted from higher sales of its generic version of Adderall. Total company revenue increased from $126 million last year to $166 million.

The results topped Wall Street analysts' estimates on both the top and the bottom line. On average, analysts had expected $0.45 in per-share earnings on $162 million in sales.

Now what: As CEO Larry Hsu pointed out, the company currently has 46 generic drugs and 40 "internally developed or partnered products" in the works, so there's a lot going on at Impax for investors to potentially look forward to. As far as the financial results for the current year, though, the company's outlook remained relatively the same as what it delivered last quarter. The only tweak that it made to the full-year outlook was to update its potential patent-litigation spending from a flat $10 million expectation to a range of $10 million to $13 million.

Want to keep up to date on Impax Laboratories? Add it to your Watchlist.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer has no financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter, @KoppTheFool, or on Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1966535, ~/Articles/ArticleHandler.aspx, 10/22/2016 5:57:27 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 20 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
IPXL $21.85 Down -0.05 -0.23%
Impax Laboratories CAPS Rating: **